Soft tissue sarcomas: Clinical practice guidelines;Guía de práctica clínica en los sarcomas de partes blandas

Medicina Clinica

Volumn 136, Issue 9, 2011, Pages

  García Del Muro, Xavier ^a   Martín, Javier ^b   Maurel, Joan ^c   Cubedo, Ricardo ^d   Bagué, Silvia ^e   De Álava, Enrique ^f   López Pousa, Antonio ^e   Narváez, José Antonio ^g   Ortiz, Eduardo ^h   Pomés, Jaume ^c   Poveda, Andrés ⁱ   Pérez Romasanta, Luis ^j   Tendero, Oscar ^b   Viñals, Joan M ^g  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^f HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^g HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^h HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

ⁱ INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^j HOSPITAL GENERAL UNIVERSITARIO DE CIUDAD REAL   (Spain)

more..

Author keywords

Clinical practice guidelines; Consensus; Sarcomas; Soft tissue sarcomas

Indexed keywords

CANCER DIAGNOSIS; CANCER THERAPY; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; HISTOLOGY; HUMAN; PATHOPHYSIOLOGY; PATIENT MONITORING; PRACTICE GUIDELINE; SOFT TISSUE SARCOMA; SPAIN;

HUMANS; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 79953684544     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2011.02.004     Document Type: Conference Paper

References (135)

1. Rydholm A. Management of patients with soft-tissue tumors. Strategy developed at a regional oncology center. Acta Orthop Scand Suppl. 1983;203:13-77.
2. Johnson CJ, Pynsent PB, Grimer RJ. Clinical features of soft tissue sarcomas. Ann R Coll Surg Engl. 2001;83:203-5. (Pubitemid 32509725)
3. Kulkarni A GR, Pynsent P. When is a lump a sarcoma? An analysis of 1100 lumps. Connective Tissue Oncology Society (CTOS). 9th Annual Meeting. Barcelona: 2003. [Abstract #177].
4. Mankin HJ, Lange TA, Spanier SS. The hazards of biopsy in patients with malignant primary bone and soft-tissue tumors. J Bone Joint Surg Am. 1982;64:1121-7. (Pubitemid 13244005)
5. Mankin HJ, Mankin CJ, Simon MA. The hazards of the biopsy, revisited. Members of the Musculoskeletal Tumor Society. J Bone Joint Surg Am. 1996;78:656-63.
6. Kandel R, Bell R, O'Sullivan B, Catton C, Ferguson P, Blackstein M, et al. Histological assessment of peritumoral edema in soft tissue sarcoma. CTOS 9th Annual Meeting. Barcelona: 2003. [Abstract # 120].
7. Stojadinovic A, Leung DH, Hoos A, Jaques DP, Lewis JJ, Brennan MF. Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg. 2002;235:424-34. (Pubitemid 34183894)
8. Trovik CS, Gustafson P, Bauer HC, Saeter G, Klepp R, Berlin O, et al. Consequences of local recurrence of soft tissue sarcoma: 205 patients from the Scandinavian Sarcoma Group Register. Acta Orthop Scand. 2000;71:488-95.
9. Eilber FC, Rosen G, Nelson SD, Selch M, Dorey F, Eckardt J, et al. High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality. Ann Surg. 2003;237:218-26. (Pubitemid 38173249)
10. Stojadinovic A, Leung DH, Allen P, Lewis JJ, Jaques DP, Brennan MF. Primary adult soft tissue sarcoma: time-dependent influence of prognostic variables. J Clin Oncol. 2002;20:4344-52. (Pubitemid 35266296)
11. National Institute for Health and Clinical Excellence. Improving outcomes for people with sarcomas. NICE Cancer Service Guidance 2006 [Consultado 21 de enero de 2011]. Disponible en: http://www.nice.org.uk/nicemedia/pdf/ SarcomaFullGuidance.pdf.
12. Wiklund T, Huuhtanen R, Blomqvist C, Tukiainen E, Virolainen M, Virkkunen P, et al. The importance of a multidisciplinary group in the treatment of soft tissue sarcomas. Eur J Cancer. 1996;32A:269-73.
13. Bauer HC, Trovik CS, Alvegard TA, Berlin O, Erlanson M, Gustafson P, et al. Monitoring referral and treatment in soft tissue sarcoma: study based on 1,851 patients from the Scandinavian Sarcoma Group Register. Acta Orthop Scand. 2001;72:150-9. (Pubitemid 32405276)
14. Paszat L, O'Sullivan B, Bell R, Bramwell V, Groome P, Mackillop W, et al. Processes and outcomes of care for soft tissue sarcoma of the extremities. Sarcoma. 2002;6:19-26. (Pubitemid 34620885)
15. Bhangu AA, Beard JA, Grimer RJ. Should Soft Tissue Sarcomas be Treated at a Specialist Centre? Sarcoma. 2004;8:1-6.
16. Ray-Coquard I, Thiesse P, Ranchere-Vince D, Chauvin F, Bobin JY, Sunyach MP, et al. Conformity to clinical practice guidelines, multidisciplinary management and outcome of treatment for soft tissue sarcomas. Ann Oncol. 2004;15:307-15. (Pubitemid 38262633)
17. Van Dalen T. Management of soft tissue sarcoma in the retroperitoneal space: a population based study in the Netherlands [Tesis doctoral]. Utrecht: University of Utrecht; 2000.
18. Nijhuis PH, Schaapveld M, Otter R, Hoekstra HJ. Soft tissue sarcoma-compliance with guidelines. Cancer. 2001;91:2186-95.
19. Fletcher CD. World Health Organization Classification of Tumours. En: Pathology and Genetics. Tumours of Soft Tissue and Bone. Lyon: IARC Press; 2002.
20. Association of Directors of Anatomic and Surgical Pathology. Recommendations for the reporting of soft tissue sarcoma. Virchows Arch. 1999;434:187-91.
21. Abdul-Karim FW, Bauer TW, Kilpatrick SE, Raymond KA, Siegal GP. Recommendations for the reporting of bone tumors. Association of Directors of Anatomic and Surgical Pathology. Hum Pathol. 2004;35:1173-8.
22. Casali PG, Jost L, Sleijfer S, Verweij J, Blay JY. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19 Suppl 2:ii89-93.
23. Picci P, Bacci G, Campanacci M, Gasparini M, Pilotti S, Cerasoli S, et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer. 1985;56:1515-21.
24. Simon Michael A, Springfield D. Surgery for bone and soft-tissue tumors. New York: Lippincott-Raven Publishers Philadelphia; 1998.
25. Gronchi A, Casali PG, Mariani L, Miceli R, Fiore M, Lo Vullo S, et al. Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: a series of patients treated at a single institution. J Clin Oncol. 2005;23:96-104. (Pubitemid 41702627)
26. Campanacci M. Bone and Soft Tissue Tumors, 2.a ed, Padova: Piccin Nuova Libraria; 1999.
27. Malawer M, Sugarbaker Paul H. Musculoskeletal Cancer Surgery. En: Treatment of Sarcomas and Allied Diseases. The Netherlands: Kluwer Academic Publishers; 2001.
28. Herbert SH, Corn BW, Solin LJ, Lanciano RM, Schultz DJ, McKenna WG, et al. Limb-preserving treatment for soft tissue sarcomas of the extremities. The significance of surgical margins. Cancer. 1993;72:1230-8.
29. Bannasch H, Haivas I, Momeni A, Stark GB. Oncosurgical and reconstructive concepts in the treatment of soft tissue sarcomas: a retrospective analysis. Arch Orthop Trauma Surg. 2009;129:43-9.
30. Wright EH, Gwilym S, Gibbons CL, Critchley P, Giele HP. Functional and oncological outcomes after limb-salvage surgery for primary sarcomas of the upper limb. J Plast Reconstr Aesthet Surg. 2008;61:382-7. (Pubitemid 351392018)
31. Mathes SJ. Plastic Surgery. En: Volume I General Principles2nd ed, Philadelphia: Sounders Elsevier; 2006.
32. Geddes CR, Morris SF, Neligan PC. Perforator flaps: evolution, classification, and applications. Ann Plast Surg. 2003;50:90-9. (Pubitemid 36070236)
33. Masquelet AC, Gilbert A. An atlas of flaps in limb reconstruction London Martin Dunitz Ltd;. 1995.
34. Servant JM, Arnault E, Revol M, Danino A. Reconstruction of large thoracoabdominal defects using two-stage free tissue transfers and prosthetic materials. J Plast Reconstr Aesthet Surg. 2006;59:360-5.
35. Hidalgo DA, Disa JJ, Cordeiro PG, Hu QY. A review of 716 consecutive free flaps for oncologic surgical defects: refinement in donor-site selection and technique. Plast Reconstr Surg. 1998;102:722-32. (Pubitemid 28402615)
36. Schwarzbach MH, Hormann Y, Hinz U, Bernd L, Willeke F, Mechtersheimer G, et al. Results of limb-sparing surgery with vascular replacement for soft tissue sarcoma in the lower extremity. J Vasc Surg. 2005;42:88-97. (Pubitemid 40966081)
37. Ghert MA, Davis AM, Griffin AM, Alyami AH, White L, Kandel RA, et al. The surgical and functional outcome of limb-salvage surgery with vascular reconstruction for soft tissue sarcoma of the extremity. Ann Surg Oncol. 2005;12:1102-10. (Pubitemid 41660687)
38. Terzis JK, Konofaos P. Nerve transfers in facial palsy. Facial Plast Surg. 2008;24:177-93. (Pubitemid 351717351)
39. Takushima A, Harii K, Asato H, Ueda K, Yamada A. Neurovascular free-muscle transfer for the treatment of established facial paralysis following ablative surgery in the parotid region. Plast Reconstr Surg. 2004;113:1563-72. (Pubitemid 39201784)
40. Chang DW, Weber KL. Use of a vascularized fibula bone flap and intercalary allograft for diaphyseal reconstruction after resection of primary extremity bone sarcomas. Plast Reconstr Surg. 2005;116:1918-25.
41. Yilmaz M, Vayvada H, Menderes A, Demirdover C, Kizilkaya A. A comparison of vascularized fibular flap and iliac crest flap for mandibular reconstruction. J Craniofac Surg. 2008;19:227-34. (Pubitemid 351158826)
42. Bach AD, Kopp J, Stark GB, Horch RE. The versatility of the free osteocutaneous fibula flap in the reconstruction of extremities after sarcoma resection. World J Surg Oncol. 2004;2:22.
43. Hameed A, Akhtar S, Naqvi A, Pervaiz Z. Reconstruction of complex chest wall defects by using polypropylene mesh and a pedicled latissimus dorsi flap: a 6-year experience. J Plast Reconstr Aesthet Surg. 2008;61:628-35. (Pubitemid 351680439)
44. Chang RR, Mehrara BJ, Hu QY, Disa JJ, Cordeiro PG. Reconstruction of complex oncologic chest wall defects: a 10-year experience. Ann Plast Surg. 2004;52:471-9. (Pubitemid 38534019)
45. Mundt AJ, Awan A, Sibley GS, Simon M, Rubin SJ, Samuels B, et al. Conservative surgery and adjuvant radiation therapy in the management of adult soft tissue sarcoma of the extremities: clinical and radiobiological results. Int J Radiat Oncol Biol Phys. 1995;32:977-85.
46. Wolfson AH, Benedetto PW, Mnaymneh W, Moffat FL, Robinson DS, Boyer C, et al. Does a radiation dose-response relation exist concerning survival of patients who have soft-tissue sarcomas of the extremities? Radiation dose-response relation for soft-tissue sarcomas. Am J Clin Oncol. 1998;21:270-4. (Pubitemid 28280139)
47. Al Yami AH, Griffin AM, Ferguson PC, Catton CN, Chung PW, Bell RS, et al. Positive surgical margins in soft tissue sarcoma treated with preoperative radiation: Is a postoperative boost necessary? Connective Tissue Oncology Society (CTOS) 12th Annual Meeting, Venice, 2006. Int J Radiat Oncol Biol Phys. 2010;77:1191-7.
48. Kraybill WG, Harris J, Spiro IJ, Ettinger DS, DeLaney TF, Blum RH, et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J Clin Oncol. 2006;24:619-25. (Pubitemid 46630425)
49. Edmonson JH, Petersen IA, Shives TC, Mahoney MR, Rock MG, Haddock MG, et al. Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony- stimulating factor. Cancer. 2002;94:786-92. (Pubitemid 34132309)
50. Alektiar KM, Brennan MF, Singer S. Influence of site on the therapeutic ratio of adjuvant radiotherapy in soft-tissue sarcoma of the extremity. Int J Radiat Oncol Biol Phys. 2005;63:202-8. (Pubitemid 41583559)
51. Delaney TF, Kepka L, Goldberg SI, Hornicek FJ, Gebhardt MC, Yoon SS, et al. Radiation therapy for control of soft-tissue sarcomas resected with positive margins. Int J Radiat Oncol Biol Phys. 2007;67:1460-9. (Pubitemid 46467161)
52. Habrand JL, Gerbaulet A, Pejovic MH, Contesso G, Durand S, Haie C, et al. Twenty years experience of interstitial iridium brachytherapy in the management of soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 1991;20:405-11.
53. Harrison LB, Franzese F, Gaynor JJ, Brennan MF. Long-term results of a prospective randomized trial of adjuvant brachytherapy in the management of completely resected soft tissue sarcomas of the extremity and superficial trunk. Int J Radiat Oncol Biol Phys. 1993;27:259-65. (Pubitemid 23304451)
54. Pisters PW, Harrison LB, Leung DH, Woodruff JM, Casper ES, Brennan MF. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol. 1996;14:859-68. (Pubitemid 26085531)
55. Rosenblatt E, Meushar N, Eidelman M, Kuten A. Low dose-rate interstitial brachytherapy in soft tissue sarcomas. Sarcoma. 1999;3:101-5. (Pubitemid 29484562)
56. Shiu MH, Turnbull AD, Nori D, Hajdu S, Hilaris B. Control of locally advanced extremity soft tissue sarcomas by function-saving resection and brachytherapy. Cancer. 1984;53:1385-92. (Pubitemid 14198901)
57. Pisters PW, Harrison LB, Woodruff JM, Gaynor JJ, Brennan MF. A prospective randomized trial of adjuvant brachytherapy in the management of low-grade soft tissue sarcomas of the extremity and superficial trunk. J Clin Oncol. 1994;12:1150-5. (Pubitemid 24173927)
58. Alekhteyar KM, Leung DH, Brennan MF, Harrison LB. The effect of combined external beam radiotherapy and brachytherapy on local control and wound complications in patients with high-grade soft tissue sarcomas of the extremity with positive microscopic margin. Int J Radiat Oncol Biol Phys. 1996;36:321-4.
59. Nag S, Shasha D, Janjan N, Petersen I, Zaider M. The American Brachytherapy Society recommendations for brachytherapy of soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 2001;49:1033-43. (Pubitemid 32184610)
60. Nag S, Gupta N. A simple method of obtaining equivalent doses for use in HDR brachytherapy. Int J Radiat Oncol Biol Phys. 2000;46:507-13. (Pubitemid 30067803)
61. Orton CG. Radiobiology. En: Nag S, editor. Principles and practice of brachytherapy. Armonk, NY: Futura Publishing Co; 1997. p. 27-45.
62. Nag S, Donath D, Porter AT. The role of high dose rate brachytherapy in the management f adult soft tissue sarcomas. En: Nag S, editor. High Dose Rate Brachytherapy. A Textbook. Armonk, NY: Futura Publishing Co;; 1994. p. 393-8.
63. Pohar S, Haq R, Liu L, Koniarczyk M, Hahn S, Damron T, et al. Adjuvant high-dose-rate and low-dose-rate brachytherapy with external beam radiation in soft tissue sarcoma: a comparison of outcomes. Brachytherapy. 2007;6:53-7. (Pubitemid 46187328)
64. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet. 1997; 350:1647-54.
65. Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19:1238-47. (Pubitemid 32202526)
66. Frustaci S, De Paoli A, Bidoli E, La Mura N, Berretta M, Buonadonna A, et al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology. 2003;65 Suppl 2:80-4.
67. Woll PJ, Van Glabbeke M, Hohenberger P, Le Cesne A, Gronchi HJ, Hoekstra JA, et al. Adjuvant chemotherapy with doxorubicin and ifosfamide in resected soft tissue sarcoma: interim analysis of a randomised phase III trial. J Clin Oncol. 2007;25 Suppl 18:10008.
68. Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113:573-81.
69. Weitz J, Antonescu CR, Brennan MF. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol. 2003;21:2719-25. (Pubitemid 46606317)
70. Gortzak E, Azzarelli A, Buesa J, Bramwell VH, Van Coevorden F, Van Geel AN, et al. A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer. 2001;37:1096-103.
71. O'Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359:2235-41. (Pubitemid 34717977)
72. Pisters PW, Ballo MT, Fenstermacher MJ, Feig BW, Hunt KK, Raymond KA, et al. Phase I trial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma. J Clin Oncol. 2003;21:3092-7. (Pubitemid 46606290)
73. DeLaney TF, Spiro IJ, Suit HD, Gebhardt MC, Hornicek FJ, Mankin HJ, et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys. 2003;56:1117-27. (Pubitemid 36794046)
74. Meric F, Hess KR, Varma DG, Hunt KK, Pisters PW, Milas KM, et al. Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. Cancer. 2002;95:1120-6. (Pubitemid 34925365)
75. Feig B, Ross M, Hunt K, Cormier J, Griffin J, Pisters P, et al. A prospective evaluation of isolated limb perfusion with doxorubicin in patients with unresectable extremity sarcomas. Ann Surg Oncol. 2004;11 Suppl 2:S80.
76. Eggermont AM, Schraffordt Koops H, Klausner JM, Kroon BB, Schlag PM, Lienard D, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg. 1996;224:756-64.
77. Eggermont AM, Koops HS, Lienard D, et al. Limb salvage by isolation limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced extremity soft tissue sarcomas: results of 270 perfusions in 246 patients. Proc Am Soc Clin Oncol. 1999;11:497.
78. Rossi CR, Mocellin S, Pilati P, Foletto M, Campana L, Quintieri L, et al. Hyperthermic isolated perfusion with low-dose tumor necrosis factor alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcomas. Ann Surg Oncol. 2005;12:398-405.
79. Grunhagen DJ, De Wilt JH, Graveland WJ, Verhoef C, Van Geel AN, Eggermont AM. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer. 2006;106:1776-84.
80. Bedard V, Vataire C, Desouche C, Le Péchoux C, Muret J, Vanel D, et al. A prospective database of 100 patients with locally soft tissue sarcoma (STS) treated by isolated limb perfusion with melphalan and TNFa 1 mg. J Clin Oncol Proc. 2007;25(18S):10010.
81. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. The International Registry of Lung Metastases. J Thorac Cardiovasc Surg. 1997; 113:37-49.
82. Billingsley KG, Burt ME, Jara E, Ginsberg RJ, Woodruff JM, Leung DH, et al. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. Ann Surg. 1999;229:602-10.
83. Van Geel AN, Pastorino U, Jauch KW, Judson IR, Van Coevorden F, Buesa JM, et al. Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer. 1996;77:675-82. (Pubitemid 26055392)
84. Choong PF, Pritchard DJ, Rock MG, Sim FH, Frassica FJ. Survival after pulmonary metastasectomy in soft tissue sarcoma. Prognostic factors in 214 patients. Acta Orthop Scand. 1995;66:561-8.
85. Edmonson JH, Ryan LM, Blum RH, Brooks JS, Shiraki M, Frytak S, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993;11:1269-75. (Pubitemid 23199129)
86. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1995;13:1537-45.
87. Buesa JM, Lopez-Pousa A, Martin J, Anton A, Garcia del Muro J, Bellmunt J, et al. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS). Ann Oncol. 1998;9:871-6. (Pubitemid 28440446)
88. Frustaci S, Buonadonna A, Galligioni E, Favaro D, De Paoli A, Lo Re G, et al. Increasing 4′-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a pilot study. J Clin Oncol. 1997;15:1418-26. (Pubitemid 27167374)
89. Reichardt P, Tilgner J, Hohenberger P, Dorken B. Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. J Clin Oncol. 1998;16:1438-43. (Pubitemid 28175763)
90. De Pas T, De Braud F, Orlando L, Nole F, Munzone E, Zampino MG, et al. High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible? Ann Oncol. 1998;9:917-9.
91. Maurel J, Fra J, Lopez-Pousa A, Garcia del Muro X, Balana C, Casado A, et al. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS). Cancer. 2004;100:1498-506. (Pubitemid 38366854)
92. Maurel J, Lopez-Pousa A, De Las Penas R, Fra J, Martin J, Cruz J, et al. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas. J Clin Oncol. 2009;27:1893-8.
93. Van Glabbeke M, Verweij J, Judson I, Nielsen OS. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer. 2002;38:543-9. (Pubitemid 34185394)
94. Van Glabbeke M, Steward W, Armand JP. Non-randomised phase II trials of drug combinations: often meaningless, sometimes misleading. Are there alternative strategies? Eur J Cancer. 2002;38:635-8. (Pubitemid 34251384)
95. Van Glabbeke M, Van Oosterom AT, Oosterhuis JW, Mouridsen H, Crowther D, Somers R, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens-a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 1999;17:150-7. (Pubitemid 29022388)
96. Maurel J, Buesa J, Lopez-Pousa A, Del Muro XG, Quintana MJ, Martin J, et al. Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): a potential positive selection bias-a study of the Spanish group for research on sarcomas (GEIS). J Surg Oncol. 2004;88:44-9. (Pubitemid 39313820)
97. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol. 2005;23:9067-72.
98. National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology v 2, 2008. [Consultado 21 de enero de 2011]. Disponible en: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp
99. Sawyer M, Bramwell V. The treatment of distant metastases in soft tissue sarcoma. Semin Radiat Oncol. 1999;9:389-400. (Pubitemid 29489388)
100. Elias AD, Eder JP, Shea T, Begg CB, Frei 3rd E, Antman KH. High-dose ifosfamide with mesna uroprotection: a phase I study. J Clin Oncol. 1990;8:170-8. (Pubitemid 20032461)
101. Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le Cesne A, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007;8:595-602. (Pubitemid 46995623)
102. Garcia-Carbonero R, Supko JG, Maki RG, Manola J, Ryan DP, Harmon D, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol. 2005;23:5484-92.
103. Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol. 2004;22:1480-90. (Pubitemid 41103631)
104. Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol. 2005;23:576-84. (Pubitemid 46224235)
105. Look KY, Sandler A, Blessing JA, Lucci 3rd JA, Rose PG. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study. Gynecol Oncol. 2004;92:644-7. (Pubitemid 38183157)
106. Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol. 2001;19:3483-9. (Pubitemid 32730085)
107. Garcia del Muro XFJ, Lopez Pousa A. Randomized phase II study of dacarbazine plus gemcitabine versus DTIC alone in patients with advanced soft tissue sarcoma: A Spanish Group for Research on Sarcomas (GEIS) study. J Clin Oncol. 2009;27 Suppl 15:10529.
108. Buesa JM, Losa R, Fernandez A, Sierra M, Esteban E, Diaz A, et al. Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation. Cancer. 2004;101:2261-9. (Pubitemid 39458682)
109. Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002;20:2824-31. (Pubitemid 34651511)
110. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol. 2007;25:2755-63. (Pubitemid 47123184)
111. Buesa JM, Mouridsen HT, Van Oosterom AT, Verweij J, Wagener T, Steward W, et al. High-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E. O. R. T. C. Soft Tissue and Bone Sarcoma Group. Ann Oncol. 1991;2:307-9.
112. Pappo AS, Rao BN, Cain A, Bodner S, Pratt CB. Dermatofibrosarcoma protuberans: the pediatric experience at St. Jude Children's Research Hospital. Pediatr Hematol Oncol. 1997;14:563-8.
113. Nouri K, Lodha R, Jimenez G, Robins P. Mohs micrographic surgery for dermatofibrosarcoma protuberans: University of Miami and NYU experience. Dermatol Surg. 2002;28:1060-4. (Pubitemid 35424808)
114. Ng A, Nishikawa H, Lander A, Grundy R. Chemosensitivity in pediatric dermatofibrosarcoma protuberans. J Pediatr Hematol Oncol. 2005;27:100-2. (Pubitemid 40271113)
115. Lev D, Kotilingam D, Wei C, Ballo MT, Zagars GK, Pisters PW, et al. Optimizing treatment of desmoid tumors. J Clin Oncol. 2007;25:1785-91. (Pubitemid 46797962)
116. Ballo MT, Zagars GK, Pollack A. Radiation therapy in the management of desmoid tumors. Int J Radiat Oncol Biol Phys. 1998;42:1007-14. (Pubitemid 29004142)
117. Chugh RMR, Thomas DG, Reinke D, Wathen JK, Patel S, Priebat DA, et al. A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis. J Clin Oncol. 2006;24 Suppl 18S:9515.
118. Heinrich MC, McArthur GA, Demetri GD, Joensuu H, Bono P, Herrmann R, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol. 2006;24:1195-203. (Pubitemid 46638818)
119. Janinis J, Patriki M, Vini L, Aravantinos G, Whelan JS. The pharmacological treatment of aggressive fibromatosis: a systematic review. Ann Oncol. 2003;14:181-90. (Pubitemid 36305427)
120. Azzarelli A, Gronchi A, Bertulli R, Tesoro JD, Baratti D, Pennacchioli E, et al. Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. Cancer. 2001;92:1259-64.
121. Weiss AJ, Horowitz S, Lackman RD. Therapy of desmoid tumors and fibromatosis using vinorelbine. Am J Clin Oncol. 1999;22:193-5. (Pubitemid 30263353)
122. Wehl G, Rossler J, Otten JE, Boehm N, Uhl M, Kontny U, et al. Response of progressive fibromatosis to therapy with liposomal doxorubicin. Onkologie. 2004;27:552-6. (Pubitemid 39664149)
123. Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol. 1994;18:535-58. (Pubitemid 24150803)
124. Menczer J, Levy T, Piura B, Chetrit A, Altaras M, Meirovitz M, et al. A comparison between different postoperative treatment modalities of uterine carcinosarcoma. Gynecol Oncol. 2005;97:166-70. (Pubitemid 40403689)
125. Leath CA, 3rd, Huh WK, Hyde Jr J, Cohn DE, Resnick KE, Taylor NP, et al. A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol. 2007;105:630-4. (Pubitemid 46734182)
126. Yamada SD, Burger RA, Brewster WR, Anton D, Kohler MF, Monk BJ. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer. 2000;88:2782-6. (Pubitemid 30417939)
127. Reed NS, Mangioni C, Malmstrom H, Scarfone G, Poveda A, Pecorelli S, et al. First results of a randomized trial comparing radiotherapy versus observation postoperatively in patients with uterine sarcomas. An EORTC-GCG Study. Int J Gynecol Cancer. 2003;13 Suppl 1:4.
128. Hensley ML, Ishill N, Soslow R, Larkin J, Abu-Rustum N, Sabbatini P, et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study. Gynecol Oncol. 2009;112:563-7.
129. Pink D, Lindner T, Mrozek A, Kretzschmar A, Thuss-Patience PC, Dorken B, et al. Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol Oncol. 2006;101:464-9. (Pubitemid 44251067)
130. Hardman MP, Roman JJ, Burnett AF, Santin AD. Metastatic uterine leiomyosarcoma regression using an aromatase inhibitor. Obstet Gynecol. 2007;110(2 Pt 2):518-20. (Pubitemid 47417749)
131. Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008;109:329-34. (Pubitemid 351754961)
132. Judson IR, Blay J, Chawla SP, Radford JA, Le Cesne A, Verweij J, et al. Trabectedin (Tr) in the treatment of advanced uterine leiomyosarcomas (U-LMS): Results of a pooled analysis of five single-agent phase II studies using the recommended dose. J Clin Oncol. 2010;28(15 Suppl):10028.
133. Stoeckle E, Coindre JM, Bonvalot S, Kantor G, Terrier P, Bonichon F, et al. Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group. Cancer. 2001;92:359-68. (Pubitemid 32664443)
134. Mark RJ, Tran LM, Sercarz J, Fu YS, Calcaterra TC, Juillard GF. Angiosarcoma of the head and neck. The UCLA experience 1955 through 1990. Arch Otolaryngol Head Neck Surg. 1993;119:973-8.
135. Fata F, O'Reilly E, Ilson D, Pfister D, Leffel D, Kelsen DP, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer. 1999;86:2034-7.